Visgeneer Inc. (TPEX:4197)
7.10
-0.32 (-4.31%)
Nov 20, 2026, 1:11 PM CST
Visgeneer Revenue
Visgeneer had revenue of 81.61M TWD in the half year ending June 30, 2026, with 77.59% growth. This brings the company's total for the last twelve months to 170.72M, up 6.86% year-over-year. In the year 2025, Visgeneer had annual revenue of 179.06M with 54.68% growth. That makes Visgeneer the 39,924th largest company in the world by revenue and 2,057th in Taiwan.
Revenue (ttm)
170.72M
Revenue Growth
+6.86%
P/S Ratio
1.26
Revenue / Employee
1.74M
Employees
98
Market Cap
214.28M
Revenue by Geography
- Asia 81.32M 45.4%
- America 62.27M 34.8%
- Europe 33.74M 18.8%
- Others 1.74M 1.0%
Fiscal year ended Dec 31, 2025 See the full Visgeneer breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 179.06M | 63.30M | 54.68% |
| Dec 31, 2024 | 115.76M | -32.24M | -21.78% |
| Dec 31, 2023 | 147.99M | -9.97M | -6.31% |
| Dec 31, 2022 | 157.96M | -7.32M | -4.43% |
| Dec 31, 2021 | 165.29M | -10.68M | -6.07% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Meribank Biotech | 408.48M |
| Taiwan Advance Bio-Pharmaceutical | 348.54M |
| GeneReach Biotechnology | 241.13M |
| RBC Bioscience | 209.59M |
| NatureWise Biotech & Medicals | 174.62M |
| Feng Chi Biotech | 156.99M |
| Vectorite Biomedical | 54.81M |
| Neith | 32.29M |